Vanda Pharmaceuticals (VNDA) Accumulated Expenses (2010 - 2026)

Vanda Pharmaceuticals has reported Accumulated Expenses for 17 years, with the latest figure at $75.0 million in Q1 2026.

• Quarterly Accumulated Expenses rose 27.83% year-over-year to $75.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.0 million (up 27.83% YoY) and the FY2025 annual result came in at $76.9 million, up 26.23% from the prior year.
• Accumulated Expenses eased to $75.0 million in Q1 2026 per VNDA's latest filing, from $76.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $76.9 million in Q4 2025 and troughed at $38.2 million in Q2 2022.
• A 5-year average of $55.7 million and a median of $55.5 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 49.19% in 2023, then dropped 5.34% in 2024.
• Over 5 years, Accumulated Expenses stood at $45.9 million in 2022, then gained by 7.31% to $49.2 million in 2023, then rose by 23.68% to $60.9 million in 2024, then advanced by 26.23% to $76.9 million in 2025, then slipped by 2.48% to $75.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $75.0 million, $76.9 million, and $70.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.